JP5404625B2 - 組成物 - Google Patents

組成物 Download PDF

Info

Publication number
JP5404625B2
JP5404625B2 JP2010521478A JP2010521478A JP5404625B2 JP 5404625 B2 JP5404625 B2 JP 5404625B2 JP 2010521478 A JP2010521478 A JP 2010521478A JP 2010521478 A JP2010521478 A JP 2010521478A JP 5404625 B2 JP5404625 B2 JP 5404625B2
Authority
JP
Japan
Prior art keywords
docetaxel
taxane
pvp
ritonavir
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010521478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536837A (ja
JP2010536837A5 (enExample
Inventor
ベイネン，ヤコブ，ヘンドリック
シュレンス，ヨハネス，ヘンリカス，マティアス
ムース，ヨハネス
ヌーイェン，バスティアーン
Original Assignee
スティヒティング ヘット ネーデルランド カンケル インスティテュート
スローテルファールト パーティシペィティズ ビーヴィ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スティヒティング ヘット ネーデルランド カンケル インスティテュート, スローテルファールト パーティシペィティズ ビーヴィ filed Critical スティヒティング ヘット ネーデルランド カンケル インスティテュート
Priority claimed from PCT/GB2008/002854 external-priority patent/WO2009027644A2/en
Publication of JP2010536837A publication Critical patent/JP2010536837A/ja
Publication of JP2010536837A5 publication Critical patent/JP2010536837A5/ja
Application granted granted Critical
Publication of JP5404625B2 publication Critical patent/JP5404625B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010521478A 2007-08-24 2008-08-22 組成物 Active JP5404625B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95776407P 2007-08-24 2007-08-24
US60/957,764 2007-08-24
GB0716591A GB0716591D0 (en) 2007-08-24 2007-08-24 Composition
GB0716591.3 2007-08-24
PCT/GB2008/002854 WO2009027644A2 (en) 2007-08-24 2008-08-22 Composition

Publications (3)

Publication Number Publication Date
JP2010536837A JP2010536837A (ja) 2010-12-02
JP2010536837A5 JP2010536837A5 (enExample) 2012-10-18
JP5404625B2 true JP5404625B2 (ja) 2014-02-05

Family

ID=38599259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521478A Active JP5404625B2 (ja) 2007-08-24 2008-08-22 組成物

Country Status (5)

Country Link
JP (1) JP5404625B2 (enExample)
CN (1) CN101854919B (enExample)
ES (1) ES2535401T3 (enExample)
GB (1) GB0716591D0 (enExample)
RU (1) RU2488384C2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2015152433A1 (en) 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
CN105106420A (zh) * 2015-07-30 2015-12-02 马衍福 一种抗肿瘤疾病中药制剂
JP2020514359A (ja) 2017-03-15 2020-05-21 ディーエフビー ソリア リミテッド ライアビリティ カンパニー タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法
CN111465389B (zh) 2017-09-07 2022-06-21 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
CN113473982A (zh) * 2018-12-21 2021-10-01 莫德拉药物股份有限责任公司 使用多西他赛和cyp3a抑制剂组合治疗实体瘤
PE20220250A1 (es) * 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1048956B (zh) * 1999-05-27 2006-07-28 阿库斯菲尔公司 多孔药物基质及其制造方法
EP1539111A1 (en) * 2002-08-05 2005-06-15 DSM IP Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
KR100508518B1 (ko) * 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Also Published As

Publication number Publication date
GB0716591D0 (en) 2007-10-03
BRPI0816144A2 (pt) 2015-02-18
JP2010536837A (ja) 2010-12-02
RU2010110658A (ru) 2011-09-27
CN101854919A (zh) 2010-10-06
RU2488384C2 (ru) 2013-07-27
ES2535401T3 (es) 2015-05-11
CN101854919B (zh) 2012-02-15

Similar Documents

Publication Publication Date Title
KR101544498B1 (ko) 종양성 질환의 치료를 위한 조성물
JP5548092B2 (ja) ナノ粒子のメロキシカム製剤
Strickley Solubilizing excipients in oral and injectable formulations
JP5404625B2 (ja) 組成物
KR20100126465A (ko) 미코페놀레이트를 포함하는 변형 방출 제약 조성물 및 그것의 방법
CA2992404C (en) Pharmaceutical composition containing celecoxib and tramadol
WO2013108254A1 (en) Formulation and method for increasing oral bioavailability of drugs
JP2016518398A (ja) 低用量医薬組成物
KR20210005714A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
WO2017204210A1 (ja) 経口医薬組成物及び該組成物からなる粒子状製剤の製造方法
JPH10259131A (ja) 経口投与用ラパマイシン処方
US20040198646A1 (en) Menthol solutions of drugs
CN107613984B (zh) 药物组合物及其用途
ES2620078T3 (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
US20150328180A1 (en) Composition
US11607384B2 (en) Lipid emulsified drug delivery systems for chemoprevention and treatment
US20060141028A1 (en) Cyclosporin formulations
HK1144390B (en) Compositions for the treatment of neoplastic diseases
KR100986531B1 (ko) 액상의 아세클로페낙을 함유하는 캡슐제
BRPI0816144B1 (pt) Composição farmacêutica sólida para administração oral, uso da mesma e método para a preparação da dita composição
CN110123752A (zh) 一种普罗布考干乳剂组合物及其制备方法和制药应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131029

R150 Certificate of patent or registration of utility model

Ref document number: 5404625

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250